Lisata Therapeutics, based in Basking Ridge, New Jersey, focuses on developing therapies for advanced solid tumors, with its lead candidate LSTA1 enhancing anti-cancer drug penetration in tumors. The company also explores CD34+ cell therapy for various diseases, including critical limb ischemia and diabetic kidney disease.
Lisata Therapeutics (LSTA) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Lisata Therapeutics's actual EPS was -$0.54, beating the estimate of -$0.66 per share, resulting in a 18.55% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
